You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Her2 Negative Metastatic Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)

Recruiting
  • Breast Cancer
  • metronomic oral vinorelbine plus anlotinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Metastatic Breast Cancer Trial (Elacestrant)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 24, 2022

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal

Active, not recruiting
  • HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
  • +2 more
  • Ulm, Baden-Württemberg, Germany
    University Hospital Ulm -Department of Gynecology
Jul 27, 2022

Breast Cancer Trial (Capecitabine and Neratinib.)

Not yet recruiting
  • Breast Cancer
  • Capecitabine and Neratinib.
  • (no location specified)
Jul 8, 2022

Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic

Active, not recruiting
  • Breast Cancer
  • New York, New York
    NYU Perlmutter Cancer Center
Aug 5, 2022

Metastatic Breast Cancer (MBC) Trial in Nanjing, Shanghai (Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate

Recruiting
  • Metastatic Breast Cancer (MBC)
  • Paclitaxel Polymeric Micelles for Injection
  • +5 more
  • Nanjing, Jiangsu, China
  • +2 more
Nov 21, 2023

Real-World Data on First-line Treatment of Hormone

Recruiting
  • Breast Cancer
    • Porto Alegre, Rio Grande Do Sul, Brazil
      CPO
    Aug 15, 2022

    Metastatic Breast Cancer Trial in Kansas City, Rochester, Saint Louis (ATI-2231, Capecitabine, Denosumab)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Kansas City, Kansas
    • +2 more
    Mar 16, 2023

    Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

    Active, not recruiting
    • Breast Cancer
    • Guangzhou, Guangdong, China
      State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
    Jan 27, 2023

    Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Metastatic Cancer
    • (no location specified)
    Jan 11, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in

    Withdrawn
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +4 more
    • Bintrafusp Alfa
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 2, 2022

    Among Talazoparib-Treated HER2-Negative mBC With gBRCA1/2m

    Completed
    • Metastatic Breast Cancer
    • Breast Neoplasms
    • New York, New York
      Pfizer Inc.
    Aug 5, 2022

    ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

    Recruiting
    • ER-positive Breast Cancer
    • +2 more
    • Madison, Wisconsin
    • +1 more
    Jul 7, 2022

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      ER-Positive Breast Cancer, HER2-negative Breast Cancer Trial in Houston (Fulvestrant Run-In, No Fulvestrant Run-In)

      Recruiting
      • ER-Positive Breast Cancer
      • HER2-negative Breast Cancer
      • Fulvestrant Run-In
      • No Fulvestrant Run-In
      • Houston, Texas
        Houston Methodist Cancer Center
      Mar 23, 2022

      Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

      Not yet recruiting
      • Estrogen-receptor-positive Breast Cancer
      • +3 more
      • elacestrant, palbociclib, abemaciclib, ribociclib
      • Chicago, Illinois
        Northwestern University
      Sep 25, 2023

      HER2-low in Unresectable and/or Metastatic Breast Cancer

      Not yet recruiting
      • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
        • (no location specified)
        Nov 6, 2023

        Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

        Not yet recruiting
        • Breast Cancer
        • Disitamab Vedotin+Anlotinib
        • (no location specified)
        Aug 14, 2023

        Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

        Not yet recruiting
        • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Sep 12, 2023

        Breast Cancer Metastatic Trial in Ravensburg (Ribociclib, Anastrozole, Letrozole)

        Active, not recruiting
        • Breast Cancer Metastatic
        • Ravensburg, Germany
          Studienzentrum Onkologie Ravensburg
        Mar 7, 2022

        Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

        Not yet recruiting
        • Triple-Negative Breast Cancer
        • Trastuzumab Deruxtecan
        • Shanghai, Shanghai, China
          Breast cancer institute of Fudan University Cancer Hospital
        Jul 12, 2023

        HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

        Recruiting
        • HER2-positive Breast Cancer
        • +17 more
        • ALX148
        • Fam-Trastuzumab Deruxtecan-Nxki
        • Chicago, Illinois
        • +1 more
        May 19, 2023

        Breast Cancer Trial (Trastuzumab Deruxtecan)

        Not yet recruiting
        • Breast Cancer
        • Trastuzumab Deruxtecan
        • (no location specified)
        Jul 10, 2023